Daniela Melchiorri
Overview
Explore the profile of Daniela Melchiorri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
552
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Melchiorri D, Rocke T, Alm R, Cameron A, Gigante V
Lancet Microbe
. 2024 Oct;
6(3):100992.
PMID: 39454608
Antimicrobial resistance continues to evolve and remains a leading cause of death worldwide, with children younger than 5 years being among those at the highest risk. Addressing antimicrobial resistance requires...
2.
Lista S, Imbimbo B, Grasso M, Fidilio A, Emanuele E, Minoretti P, et al.
J Neuroinflammation
. 2024 Jul;
21(1):187.
PMID: 39080712
Background: Recent trials of anti-amyloid-β (Aβ) monoclonal antibodies, including lecanemab and donanemab, in early Alzheimer disease (AD) showed that these drugs have limited clinical benefits and their use comes with...
3.
Gigante V, Alm R, Melchiorri D, Rocke T, Arias C, Czaplewski L, et al.
Antimicrob Agents Chemother
. 2024 Jul;
68(8):e0053524.
PMID: 39007560
Antimicrobial resistance (AMR) is a major global health threat estimated to have caused the deaths of 1.27 million people in 2019, which is more than HIV/AIDS and malaria deaths combined....
4.
Sima M, Laslop A, Borg J, Ponist S, Melchiorri D, Drafi F
Front Pharmacol
. 2023 Jun;
14:1228406.
PMID: 37383710
No abstract available.
5.
Melchiorri D, Merlo S, Micallef B, Borg J, Drafi F
Front Pharmacol
. 2023 Jun;
14:1196413.
PMID: 37332353
Despite extensive research, no disease-modifying therapeutic option, able to prevent, cure or halt the progression of Alzheimer's disease [AD], is currently available. AD, a devastating neurodegenerative pathology leading to dementia...
6.
Moscetti L, Hennik P, Bolstad B, Camarero J, Josephson F, Melchiorri D, et al.
ESMO Open
. 2020 Aug;
5(4).
PMID: 32847837
The therapeutic landscape in the treatment of advanced/metastatic renal cell cancer has evolved over the last 2 years with the advent of immune checkpoint inhibitors. In 2018 and 2019, marketing...
7.
Ali S, Moreau A, Melchiorri D, Camarero J, Josephson F, Olimpier O, et al.
Oncologist
. 2020 Apr;
25(4):e709-e715.
PMID: 32297447
On November 15, 2018, the Committee for Medicinal Products for Human Use (CHMP) recommended the extension of indication for blinatumomab to include the treatment of adults with minimal residual disease...
8.
Herold R, Camarero J, Melchiorri D, Sebris Z, Enzmann H, Pignatti F
Eur J Cancer
. 2019 Oct;
123:25-27.
PMID: 31655357
No abstract available.
9.
Tzogani K, Florez B, Markey G, Caleno M, Olimpieri O, Melchiorri D, et al.
ESMO Open
. 2019 Sep;
4(5):e000570.
PMID: 31555488
On 21 November 2016, the European Commission issued a marketing authorisation valid throughout the European Union for ixazomib in combination with lenalidomide and dexamethasone for the treatment of adult patients...
10.
Borg J, Melchiorri D, Sepodes B, Caramella C, Tomino C, Micallef B, et al.
Pharmacol Res
. 2018 Oct;
139:491-493.
PMID: 30321599
No abstract available.